Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
New guidelines from the UK on chronic lymphocytic leukemia
Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460
Key clinical point: Fludarabine, cyclophosphamide, and rituximab should be first-line therapy for patients with chronic lymphocytic leukemia (CLL) without TP53 disruption.
Major finding: All patients diagnosed with CLL should be tested for TP53 disruption.
Study details: A guideline developed by the British Society for Haematology offering recommendations for CLL treatment outside clinical trials.
Disclosures: The guideline development was supported by the British Society for Haematology. The UK CLL Forum is a registered charity that receives funding from a number of pharmaceutical companies.
Citation:
Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460.
